Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai InnoStar Bio-tech Co EV-to-EBITDA?
Shanghai InnoStar Bio-tech CoSHSE:688710 +0.72%37 EV-to-EBITDA is 94.89 as of Sep. 21, 2026, which is 192% above its 10-year median of 32.45. GuruFocus rates SHSE:688710 with a GF Score™ of 37/100. The stock has 6 warning signs investors should review. Among 745 Drug Manufacturers companies, Shanghai InnoStar Bio-tech Co ranks worse than 95.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shanghai InnoStar Bio-tech Co's enterprise value is ¥12,153.9 Mil.
Shanghai InnoStar Bio-tech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥128.1 Mil. Therefore, Shanghai InnoStar Bio-tech Co's EV-to-EBITDA for today is 94.89.
The historical rank and industry rank for Shanghai InnoStar Bio-tech Co's EV-to-EBITDA or its related term are showing as below:
SHSE:688710'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -805.66 Med: 32.45 Max: 4035.81
Current: 94.89
During the past 7 years, the highest EV-to-EBITDA of Shanghai InnoStar Bio-tech Co was 4035.81. The lowest was -805.66. And the median was 32.45.
SHSE:688710's EV-to-EBITDA is ranked worse than 95.97% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs SHSE:688710: 94.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Shanghai InnoStar Bio-tech Co (SHSE:688710) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai InnoStar Bio-tech Co's PE Ratio (TTM) for today is calculated as:
Shanghai InnoStar Bio-tech Co's share price for today is ¥95.60.
Shanghai InnoStar Bio-tech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.169.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688710 vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Shanghai InnoStar Bio-tech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai InnoStar Bio-tech Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai InnoStar Bio-tech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shanghai InnoStar Bio-tech Co's EV-to-EBITDA falls into.
Shanghai InnoStar Bio-tech Co's current Enterprise Value is ¥12,153.9 Mil.
Shanghai InnoStar Bio-tech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥128.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a EV-to-EBITDA of 94.89 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai InnoStar Bio-tech Co. This is 192% above median its historical median of 32.45. According to the industry distribution chart, Shanghai InnoStar Bio-tech Co ranks #715 out of 745 companies in the Drug Manufacturers industry, placing it in the top 96%.
Is Shanghai InnoStar Bio-tech Co's EV-to-EBITDA too high?
Shanghai InnoStar Bio-tech Co's current EV-to-EBITDA of 94.89 is 192% above median its 10-year median of 32.45. The Drug Manufacturers industry median EV-to-EBITDA is 12.56. Shanghai InnoStar Bio-tech Co's value of 94.89 is 655.5% above this industry median. Based on the distribution chart, Shanghai InnoStar Bio-tech Co ranks #715 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai InnoStar Bio-tech Co has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai InnoStar Bio-tech Co's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai InnoStar Bio-tech Co ranks #715 out of 745 companies for EV-to-EBITDA. This places Shanghai InnoStar Bio-tech Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.56. Shanghai InnoStar Bio-tech Co's value of 94.89 is 655.5% above this benchmark. While the company's 10-year median is 32.45 vs. the industry median of 12.56, Shanghai InnoStar Bio-tech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai InnoStar Bio-tech Co's current EV-to-EBITDA of 94.89 is 655.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai InnoStar Bio-tech Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai InnoStar Bio-tech Co's current EV-to-EBITDA is 94.89, which is 192% above median its own 10-year median of 32.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai InnoStar Bio-tech Co stock overvalued right now?
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a current EV-to-EBITDA of 94.89. The current EV-to-EBITDA is 94.89, which is 192% above median its 10-year median of 32.45 and 655.5% above the Drug Manufacturers industry median of 12.56. Shanghai InnoStar Bio-tech Co's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shanghai InnoStar Bio-tech Co (SHSE:688710), the current EV-to-EBITDA is 94.89 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai InnoStar Bio-tech Co Ltd is a comprehensive research and development services (CRO) enterprise that specializes in providing biomedical non-clinical research services.
37GF Score
Get the complete analysis for SHSE:688710
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688710 has been successfully added to your 
